The COB, CEO & Pres of Omeros Corp is Exercising Options

By Carrie Williams

Yesterday, the COB, CEO & Pres of Omeros Corp, Gregory Demopulos, exercised options of Omeros Corp for $413.8K. The options were close to expired and Gregory Demopulos retained stocks.

Following Gregory Demopulos’ last OMER Buy transaction on January 15, 2016, the stock climbed by 9.6%. Following this transaction Gregory Demopulos’ holding in the company was increased by 7.7% to a total of $39.67 million.

Based on Omeros Corp’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $21.66 million and GAAP net loss of $7.48 million. In comparison, last year the company earned revenue of $11.29 million and had a GAAP net loss of $13.96 million. The company has a one-year high of $27.09 and a one-year low of $8.71. The Company has a book value per share of 101.9536.

Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $30, reflecting a -34.8% downside. 11 different firms, including B.Riley FBR and Cantor Fitzgerald, currently also have a Buy rating on the stock. Starting in November 2017, OMER received 4 Buy ratings in a row.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omeros Corp. operates as a biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The company was founded by Gregory A.